SAN Sanofi

Press release: Online availability of Sanofi’s half-year financial report for 2023

Press release: Online availability of Sanofi’s half-year financial report for 2023

Online availability of Sanofi’s half-year financial report for 2023

Paris, July 28, 2023. Sanofi announces that its half-year financial report for the period ending June 30, 2023 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K.

This document may be found on the company’s corporate website: and downloaded from the “Investors” page, under the heading “Regulated Information in France”.

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations

Sandrine Guendoul |  25 | 

Nicolas Obrist |  55 | 

Victor Rouault |  40 | 

Investor Relations

Eva Schaefer-Jansen |  39 | 

Arnaud Delépine |  93 |

Corentine Driancourt |  21 |

Felix Lauscher | + 1 908 612 7239 |

Tarik Elgoutni| 7 |

Nathalie Pham |  17 |

Attachment



EN
28/07/2023

Underlying

SANSanofi

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE
Free
SAN SANOFI

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic g...

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight o...

March 31, 2026 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Le Rezurock de Sanofi approuvé dans l’UE pour l...

Communiqué de presse : Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte Rezurock est maintenant approuvé dans l’UE pour les adultes et les enfants âgés de 12 ans et plus atteints de GvHD chronique, offrant ainsi un nouveau médicament aux patients disposant d’options thérapeutiques limitées. Paris, le 31 mars, 2026. La Commission européenne a accordé une autorisation de mise sur le marché conditionnelle pour Rezurock (belu...

March 31, 2026 1 EN
Research Department
  • Research Department
EUR 100.00
SAN SANOFI
BKT BANKINTER SA ... (+3)

INFORME DIARIO 30 MARZO (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: BANKINTER, BBVA. EUROPA: SANOFI. La entrada de los Hutíes empeora las perspectivas del conflicto en Oriente Medio Las bolsas se movieron durante la semana en un entorno de volatilidad, pendientes del conflicto en Oriente Medio después de que Trump volviera a ampliar el plazo hasta el 6 de abril para atacar infraestructuras energéticas en Irán. La entrada de las milicias Hutíes de Yemen, apoyadas por Irán, en el conflicto y sus posibles actuaciones e...

SAN SANOFI
BKT BANKINTER SA
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
03/30/26 March 30, 2026 1 ES
 PRESS RELEASE
Free
SAN SANOFI

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 stud...

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed either Q4W or Q12W, showed progressively increasing efficacy, with no evidence of plateau at Week 24 across endpointsData reinforce potential for Q12W dosing from the start Paris, March 28, 2026. Positive results from three phase 3 studies of amlitelimab, ...

March 28, 2026 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : AAD : Sanofi présente de nouveaux résultats de ...

Communiqué de presse : AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute Dans les études de phase 3 COAST 1, COAST 2 et SHORE, l’amlitelimab, administré 1x/4 sem. ou 1x/12 sem., a montré une augmentation progressive de l’efficacité, sans signe de plateau à la semaine 24 pour l’ensemble des critères d’évaluation.Les données confortent le potentiel d’une administr...

March 28, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch